MAGE-A和NY-ESO-1在宫颈癌中的表达：预后因素及化疗效果
MAGE-A and NY-ESO-1 expression in cervical cancer: prognostic factors and effects of chemotherapy.
作者信息
Napoletano Chiara, Bellati Filippo, Tarquini Elisabetta, Tomao Federica, Taurino Federica, Spagnoli Giulio, Rughetti Aurelia, Muzii Ludovico, Nuti Marianna, Benedetti Panici Pierluigi
机构信息
Department of Experimental Medicine, La Sapienza University, Rome, Italy.
出版信息
Am J Obstet Gynecol. 2008 Jan;198(1):99.e1-7. doi: 10.1016/j.ajog.2007.05.019.
OBJECTIVE
The aim of this study was to evaluate the prevalence of cancer testis tumor-associated antigens MAGE-A and NY-ESO-1 in cervical cancer and correlate expression patterns with clinicopathologic parameters and prognosis.
STUDY DESIGN
One hundred sixty-two cervical cancer samples from 109 patients who were treated with radical hysterectomy, neoadjuvant chemotherapy, or pelvic disease recurrence were analyzed by immunohistochemistry.
RESULTS
MAGE-A was expressed by 32/94 (34%) and 7/15 (47%) previously untreated and recurrent tumors, respectively. NY-ESO-1 was expressed by 46/94 (49%) and 6/15 (40%) previously untreated and recurrent tumors, respectively. MAGE-A in early stage tumors was correlated to tumor size and lymph node metastases (P = .024 and P = .046, respectively) whereas NY-ESO-1 to tumor grading (P = .039).
CONCLUSION
Cervical cancer frequently expresses cancer testis tumor-associated antigens. MAGE-A and NY-ESO-1 expression rates are not influenced by systemic therapies. Cancer testis tumor-associated antigens are correlated to common prognostic factors.
目的
本研究旨在评估癌睾丸肿瘤相关抗原MAGE - A和NY - ESO - 1在宫颈癌中的患病率，并将表达模式与临床病理参数及预后相关联。
研究设计
对109例接受根治性子宫切除术、新辅助化疗或盆腔疾病复发治疗的患者的162份宫颈癌样本进行免疫组织化学分析。
结果
MAGE - A在先前未治疗和复发肿瘤中的表达率分别为32/94（34%）和7/15（47%）。NY - ESO - 1在先前未治疗和复发肿瘤中的表达率分别为46/94（49%）和6/15（40%）。早期肿瘤中的MAGE - A与肿瘤大小和淋巴结转移相关（分别为P = 0.024和P = 0.046），而NY - ESO - 1与肿瘤分级相关（P = 0.039）。
结论
宫颈癌常表达癌睾丸肿瘤相关抗原。MAGE - A和NY - ESO - 1的表达率不受全身治疗的影响。癌睾丸肿瘤相关抗原与常见预后因素相关。
Zotero 插件